Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BIOCODEX operates within the Biotechnology & Pharmaceuticals technology area and currently has 1 pending office action. This action is assigned to 1 distinct examiner, BOECKELMAN, JACOB A. The prosecution of this portfolio is currently focused on a single matter, which allows the applicant to dedicate resources to a specific set of claims and technical arguments.
The data shows that 1 distinct art unit is involved in the review of the company's application. BOECKELMAN, JACOB A is the busiest examiner for the portfolio, with 1 busiest examiner pending action. This means that the entire pending workload is managed by 1 distinct examiner within 1 distinct art unit, ensuring that the examination process is not fragmented across different USPTO departments.
For a practitioner, the presence of 1 pending office action and 1 distinct examiner simplifies the coordination of the prosecution strategy. The involvement of only 1 distinct art unit allows for a deep focus on the specific examination standards and prior art typically cited by that group. Since the busiest examiner pending count is 1, there are no other pending matters that require simultaneous management or cross-case coordination at this time.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024444 | PHARMACEUTICAL COMPOSITION USEFUL FOR PROMOTING OSTEOBLASTOGENESIS | BOECKELMAN, JACOB A | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18024444 | PHARMACEUTICAL COMPOSITION USEFUL FOR PROMOTING OSTEOBLASTOGENESIS | BOECKELMAN, JACOB A | 1655 | §103 | Non-Final OA | — | Pending | Mar 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial